Results 41 to 50 of about 38,595 (290)

Factors influencing the selection of an SGLT2i vs. a GLP-1RA as cardioprotective agent in patients with type 2 diabetes. [PDF]

Front Cardiovasc Med
PurposeSodium glucose co-transporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated cardioprotective effects in people with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD).
Agarwal S, Basit MA, Bowen ME, Heitjan DF, Mai C, Marble K, Pak J, Xiang Z, Lingvay I.   +8 more
europepmc   +2 more sources

GLP‐1 Receptor Agonists and Endoscopy: Understanding Gastric Stasis, Aspiration Risk, and Contemporary Peri‐Procedural Guidance

Chronic Diseases and Translational Medicine, EarlyView.
Pharmacological mechanisms and physiologic effects of GLP‐1 receptor agonists relevant to peri‐endoscopic risk. ABSTRACT The global increase in obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction‐associated steatotic liver disease (MASLD) has led to a higher use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) among patients ...
Junaid Beig, Jason Ta, Sophie Jones, Emily Scott, Khalid Sofi, Frances Osler, Marije Jansen, Puneet Chhabra   +7 more
wiley   +1 more source

Long-term prognostic impact of glucagon-like peptide-1 receptor agonist before ST-segment elevation myocardial infarction in patients with type 2 diabetes: a nationwide cohort study

Cardiovascular Diabetology
Background Glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment reduces cardiovascular events in type 2 diabetes. Yet, the impact of GLP-1RA treatment before ST-segment elevation myocardial infarction (STEMI) on long-term prognosis in patients ...
Jasmine Melissa Madsen, Alexander Krüger Kjaer, Jacob Thomsen Lønborg, Lars Køber, Charlotte Glinge, Reza Jabbari, Thomas Engstrøm   +6 more
doaj   +1 more source

Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study

Cardiovascular Diabetology, 2021
Aim We aimed to compare cardiovascular outcomes of patients with type 2 diabetes (T2D) who initiated GLP-1 receptor agonists (GLP-1RA) or basal insulin (BI) under routine care.
Enrico Longato, Barbara Di Camillo, Giovanni Sparacino, Lara Tramontan, Angelo Avogaro, Gian Paolo Fadini   +5 more
doaj   +1 more source

Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial

, 2021
International audienceAimsFinerenone significantly reduced the risk of kidney and cardiovascular (CV) outcomes in patients with chronic kidney disease and type 2 diabetes in the FIDELIO-DKD trial (NCT02540993).
Filippatos, Gerasimos S., Anker, Stefan D, Gerasimos Filippatos, Lage, Andrea, Amer Joseph, Agarwal, Rajiv L., FIDELIO-DKD, Bakris, George, L, Charlie Scott, Filippatos, Gerasimos, Scott, Charlie, Ruilope, Luis,, Anker, Stefan, D, Ruilope Urioste, Luis Miguel, Agarwal, Rajiv, Stefan D. Anker, Bakris, George,, Rossing, Peter, Rajiv Agarwal, Joseph, Amer, Andrea Lage, Et al., Peter Rossing, Luis M. Ruilope, Ruilope, Luis, M, Bakris, George L., Bertram Pitt, Anker, Stefan D., Ruilope, Luis M., George L. Bakris, Michel Marre, Anker, Stefan,, Bakris, George L, FIDELIO-DKD Investigators, Marre, Michel, Aslam Amod, Pitt, Bertram, Amod, Aslam, Ruilope, Luis M   +38 more
core   +1 more source

Multi‐omics biomarkers for intestinal infection and inflammation in inflammatory bowel disease: Current evidence, translational challenges, and diagnostic opportunities

Interdisciplinary Medicine, EarlyView.
Prospective multi‐site cohorts, multi‐omics profiling, and computational analysis may help identify biomarker patterns across clinical settings in IBD and superimposed infections. With further mechanistic and clinical validation, these signals could support the development of practical multi‐analyte tools for more precise diagnosis and management ...
Ziyu Yang, Jiayi Yao, Xinxian Zhao, Yan Xu, Yifan Chen, Tianchi Chen, Ying Jian, Min Li   +7 more
wiley   +1 more source

Impact of Perioperative Glucagon-Like Peptide-1 Receptor Agonists on Postoperative Outcomes Following Carpal Tunnel Release

Journal of Hand Surgery Global Online
Purpose: Glucagon-like peptide-1 receptor agonist (GLP-1RA) use continues to rise because of its efficacy in glycemic control and weight reduction. There are sparse data on the implications of GLP-1RA therapy on surgical outcomes.
Nicholas C. Bank, MD, Stephen J. Perle, BS, Bradley J. Lauck, BA, Alecia J. Rajesh, BS, Alexander D. Jeffs, MD, Reid W. Draeger, MD   +5 more
doaj   +1 more source

Rational Design by Structural Biology of Industrializable, Long-Acting Antihyperglycemic GLP-1 Receptor Agonists

Pharmaceuticals, 2022
Glucagon-like peptide-1 (GLP-1) is easily degraded by dipeptidyl peptidase-4 (DPP-4) in the human body, limiting its therapeutic effect on type II diabetes.
Lei Sun, Zhi-Ming Zheng, Chang-Sheng Shao, Zhi-Yong Zhang, Ming-Wei Li, Li Wang, Han Wang, Gen-Hai Zhao, Peng Wang   +8 more
doaj   +1 more source

Standardized MRI‐Based Quantification of Epicardial Adipose Tissue Volume: Reproducibility and Agreement With Cardiac Computed Tomography

Journal of Magnetic Resonance Imaging, EarlyView.
ABSTRACT Background Epicardial adipose tissue volume (EATV) is increasingly recognized as a cardiometabolic risk marker associated with adverse outcomes. The most established approach for EATV quantification is cardiac computed tomography (CT). MRI offers a radiation‐free alternative allowing simultaneous assessment of myocardial function and tissue ...
Judith Gronwald, Svante S. Gersch, Zoé Böttiger, Clara Hagedorn, Torben Lange, Sören J. Backhaus, Sebastian Kelle, Constanze Schmidt, Karl Toischer, Andreas Schuster, Alexander Schulz   +10 more
wiley   +1 more source

Associations Between GLP‐1 Receptor Agonists and Alopecia: A Multi‐Centre Retrospective Analysis and Public Interest Trends

JEADV Clinical Practice, EarlyView.
ABSTRACT Background There is a growing body of literature suggesting that GLP‐1 receptor agonists (GLP‐1RAs) may be associated with hair loss; however, primary literature is sparse. Additionally, it is not well‐established which types of hair loss may be associated with GLP‐1RA use. Objectives This study aims to assess associations between GLP‐1RAs and
Lauren M. Ching, Christopher A. Guirguis, Joe K. Tung   +2 more
wiley   +1 more source